SCHEMBL79539

SCHEMBL79539

CC(C)c1ccsc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formaldehyde SCHEMBL28362816 0.93 ALOX5 (0.47) —
SCHEMBL826272 0.87 ALOX5 (0.40) —
SCHEMBL30295390 0.83 ALOX5 (0.47) —
SCHEMBL19718394 0.79 — —
SCHEMBL5002209 0.79 — —
SCHEMBL5101400 0.79 — —
SCHEMBL18827337 0.79 ALOX5 (0.44) —
SCHEMBL1309777 0.79 — —
SCHEMBL1300584 0.79 — —
SCHEMBL1310355 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1732 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104507977-B Offset lithographic printing ink with water and filler content 太阳化学公司 2019-10-11 — — CN claimed
CN-121293704-A Antistatic flame-retardant polylactic acid 3D printing material and preparation method thereof 吉安职业技术学院 2026-01-09 — — CN disclosed
US-12435054-B2 Therapeutic compounds and methods of use GENENTECH, INC. (US) 2025-10-07 — — US disclosed
EP-4185386-B1 HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER GENENTECH INC (US) 2025-01-08 — — EP disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T REMIX THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 — — US disclosed
US-20240239772-A1 PROTEASE INHIBITORS AND METHODS OF USE THE CLEVELAND CLINIC FOUNDATION 2024-07-18 — — US disclosed
US-20240239772-A1 PROTEASE INHIBITORS AND METHODS OF USE THE CLEVELAND CLINIC FOUNDATION 2024-07-18 — — US disclosed
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
EP-1031622-A1 Process for the production of low sulphur gasolines INSTITUT FRANCAIS DU PETROLE (FR) 2000-08-30 — — EP disclosed
EP-0725126-B1 Process for desulfurizing catalytically cracked gasoline NIPPON MITSUBISHI OIL CORP (JP) 2000-08-09 — — EP disclosed
EP-1002853-A1 Process for the production of low sulfur gasolines Institut Français du Pétrole (FR) 2000-05-24 — — EP disclosed
CN-1253993-A Production method of low-sulfur gasoline INST FRANCAIS DU PETROLE (FR) 2000-05-24 — — CN disclosed
EP-0725126-A1 Process for desulfurizing catalytically cracked gasoline MITSUBISHI OIL CO., LTD. (JP) 1996-08-07 — — EP disclosed
US-4795687-A POLYTHIENYLENE, POLYPRYRROLE OR POLYANILINE MATERIAL PREPARED BY OXIDATION POLYMERIZATION MITSUBISHI KASEI CORP. (JP) 1989-01-03 — — US disclosed
EP-0261837-A2 Electrically conductive material and a process for the preparation of same and secondary battery using the electrically conductive material Sanyo Electric Co., Ltd (JP) 1988-03-30 — — EP disclosed
US-4711742-A Solution processible forms of neutral and electrically conductive poly(substituted heterocycles) ALLIED CORPORATION (US) 1987-12-08 — — US disclosed
EP-0203438-A1 Solution processible forms of neutral and electrically conductive poly(substituted heterocycles) ALLIED CORPORATION (US) 1986-12-03 — — EP disclosed
EP-0173126-A1 Process for preparing novel dihydropyridine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-03-05 — — EP disclosed
Send feedback